Damora Therapeutics, Inc. short interest in 2025
In 2025, Damora Therapeutics, Inc.'s disclosed short interest ran from 1.36% of shares outstanding on 15 Jan 2025 to 12.99% on 31 Dec 2025, a change of +11.63 percentage points. The year's high was 25.42% on 14 Nov 2025 and its low 0.95% on 29 Aug 2025, averaging 5.51% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.68 days on 30 Jun 2025. Full history: Damora Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 1.36% (15 Jan 2025)
- End of year
- 12.99% (31 Dec 2025)
- Change
- +11.63 pp
- High
- 25.42% (14 Nov 2025)
- Low
- 0.95% (29 Aug 2025)
- Average
- 5.51%
- Highest days to cover
- 2.68 (30 Jun 2025)
- SEC filings marked
- 4
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 1.36% | 1.24 | |
| 31 Jan 2025 | 0.99% | 1.00 | |
| 14 Feb 2025 | 1.55% | 1.21 | |
| 28 Feb 2025 | 1.39% | 1.00 | |
| 14 Mar 2025 | 2.10% | 2.57 | |
| 31 Mar 2025 | 4.89% | 1.00 | 10-K filed |
| 15 Apr 2025 | 4.36% | 1.39 | |
| 30 Apr 2025 | 5.27% | 1.67 | |
| 15 May 2025 | 4.19% | 2.21 | 10-Q filed |
| 30 May 2025 | 5.71% | 1.00 | |
| 13 Jun 2025 | 3.40% | 1.83 | |
| 30 Jun 2025 | 2.79% | 2.68 | |
| 15 Jul 2025 | 3.00% | 1.44 | |
| 31 Jul 2025 | 2.08% | 1.01 | |
| 15 Aug 2025 | 1.45% | 1.00 | 10-Q filed |
| 29 Aug 2025 | 0.95% | 2.33 | |
| 14 Nov 2025 | 25.42% | 1.00 | 10-Q filed |
| 28 Nov 2025 | 12.62% | 1.00 | |
| 15 Dec 2025 | 13.64% | 1.15 | |
| 31 Dec 2025 | 12.99% | 2.31 |
See also: Damora Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.